EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors

Meiqin Yuan, Wanxia Fang, Bixia Liu, Yahan Tong, Junchi Cheng, Haijun Zhong, Wangxia Lv

British Journal of Hospital Medicine · 2026

DOI: 10.31083/bjhm50279 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Hospital Medicine, 2026. Verfasst von Meiqin Yuan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, 310022 Hangzhou, Zhej…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Deoxycytidine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Background: Advanced biliary tract cancer (BTC) is an aggressive malignancy, and often presents with poor prognostic outcomes despite standard chemotherapy. This study aimed to evaluate the preliminary efficacy and safety of toripalimab in combination with gemcitabine + oxaliplatin (GEMOX) as a first-line treatment option for advanced BTC.

Methods

This prospective, single-arm, single-center study enrolled 35 patients with advanced BTC. The patients received toripalimab in combination with GEMOX as first-line treatment at Zhejiang Cancer Hospital, China, between February 2021 and April 2023. Each patient received 1 to 11 treatment cycles, and the objective response rate (ORR) was evaluated before and after chemotherapy using the Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method. Furthermore, adverse events and their severity were recorded to evaluate the safety profile of the treatment.

Results

A study cohort of 35 patients was enrolled (median age, 57 years), including 15 men and 20 women. Of them, 18 had intrahepatic cholangiocarcinoma, 14 had gallbladder cancer, and 3 had hilar cholangiocarcinoma. Metastatic lesions were most commonly observed in the lymph nodes, liver, and pelvis. The ORR was 20% (95% confidence interval [CI] 8.4%–36.9%), including 2 for complete response (CR) and 5 for partial response (PR). The median PFS and OS were found to be 8.5 and 16.5 months, respectively. All patients experienced adverse events, with 11 (31.42%) of the patients having grade 3 or higher adverse events. The most commonly observed adverse events included increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), leukopenia, neutropenia, and thrombocytopenia.

Conclusion

Toripalimab combined with GEMOX showed preliminary antitumor activity and an acceptable safety profile in patients with advanced BTC, warranting further validation in larger cohorts. Clinical Trial Registration: Chinese Clinical Trial Registry (ChiCTR2600117154).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsDeoxycytidineAdultAgedFemaleHumansMaleMiddle AgedChinaGemcitabineOxaliplatinProspective StudiesOrganoplatinum Compounds

Stichwörter der Autor:innen

GEMOXbiliary tract cancerchemotherapyimmunotherapytoripalimab

Substanzen

Antibodies, Monoclonal, HumanizedDeoxycytidineGemcitabineOxaliplatintoripalimabOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Colorectal Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, 310022 Hangzhou, Zhejiang, China.
  • Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, 310022 Hangzhou, Zhejiang, China.

Zitieren

APA

Yuan, M., Fang, W., Liu, B., Tong, Y., Cheng, J., Zhong, H., & Lv, W. (2026). Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors. British Journal of Hospital Medicine. https://doi.org/10.31083/bjhm50279

Vancouver

Yuan M, Fang W, Liu B, Tong Y, Cheng J, Zhong H, et al. Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors. British Journal of Hospital Medicine. 2026. doi:10.31083/bjhm50279

BibTeX
@article{Yuan2026,
  author = {Yuan, Meiqin and Fang, Wanxia and Liu, Bixia and Tong, Yahan and Cheng, Junchi and Zhong, Haijun and Lv, Wangxia},
  title = {Preliminary Application of Toripalimab in Combination With GEMOX Regimen as a First-Line Treatment Option for Advanced Biliary Tract Tumors},
  journal = {British Journal of Hospital Medicine},
  year = {2026},
  doi = {10.31083/bjhm50279}
}
Kostenlos starten →